Breaking News
Get 55% Off 0
👀 Ones to watch: The MOST undervalued shares to buy right now
See Undervalued Shares
Close

Aesculape Sri Ic (0P0001MYLN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
255.450 +5.220    +2.09%
22/11 - Closed. Currency in EUR
  • Morningstar Rating:
  • Total Assets: 150.66M
Type:  Fund
Market:  France
Issuer:  Montpensier Finance
ISIN:  FR00140032U2 
Asset Class:  Equity
Aesculape IC 255.450 +5.220 +2.09%

0P0001MYLN Overview

 
Find basic information about the Aesculape Sri Ic mutual fund such as total assets, risk rating, Min. investment, market cap and category. Learn about the fund's agencies rating and risk rating, transparent information about the fund's management personal, policies of invested allocation and diversification, past performance. In addition we provide you related news, analysis tools, interactive charts and analysis articles. You may add 0P0001MYLN MF to your portfolio and watchlist to keep track with the fund's performance and users commentary. (ISIN: FR00140032U2)
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Rating
1-Year Change8.65%
Prev. Close250.23
Risk Rating
TTM Yield0%
ROE21.03%
IssuerMontpensier Finance
TurnoverN/A
ROA5.55%
Inception DateJul 12, 2021
Total Assets150.66M
ExpensesN/A
Min. Investment1
Market Cap41.73B
CategorySector Equity Healthcare
What is your sentiment on Aesculape IC?
or
Market is currently closed. Voting is open during market hours.

Performance

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

YTD 3M 1Y 3Y 5Y 10Y
Growth of 1000 1071 943 1160 965 - -
Fund Return 7.08% -5.67% 16.01% -1.19% - -
Place in category 570 919 594 443 - -
% in Category 57 91 62 65 - -

Top Equity Funds by Montpensier Finance

  Name Rating Total Assets YTD% 3Y% 10Y%
  FR0013073731 683.59M 1.64 -0.01 6.24
  FR0013446812 167.89M -15.98 -18.93 -
  FR0013083656 51.64M -1.89 -3.93 4.62

Top Funds for Sector Equity Healthcare Category

  Name Rating Total Assets YTD% 3Y% 10Y%
  FR0012300374 580.74M 10.20 -0.68 -
  Martin Maurel Senior Plus P 131.04M 2.14 -2.78 7.60
  FR0012283406 15.76M 4.96 -12.08 -

Top Holdings

Name ISIN Weight % Last Change %
  Eli Lilly US5324571083 5.78 749.73 +0.23%
  Thermo Fisher Scientific US8835561023 4.96 513.89 +0.12%
  J&J US4781601046 4.05 156.05 +0.57%
  Novartis CH0012005267 3.96 91.93 -1.87%
  Novo Nordisk B DK0062498333 3.74 745.4 -0.73%

Technical Summary

Type Daily Weekly Monthly
Moving Averages Sell Sell Sell
Technical Indicators Strong Sell Strong Sell BUY
Summary Strong Sell Strong Sell Neutral
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0001MYLN Comments

Write your thoughts about Aesculape Sri Ic
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email